Amgen to acquire Catherex, a subsidiary of MediGene AG, developer of T Cell therapy platforms and Imlygic (talimogene laherparepvec, formerly T-Vec)
Medigene AG, a clinical stage immunotherapy company focussing on the development of T-cell therapy platforms for the treatment of cancer, announced that Amgen will acquire 100% of Catherex, a spin-off of Medigene. The former shareholders of Catherex will receive payments upon achievement of certain regulatory and sales-based milestones for Amgen's drug Imlygic (talimogene laherparepvec, formerly T-Vec). In addition, royalty payments on the sale of Imlygic will be made until the end of 2020. Amgen's drug Imlygic was approved for the treatment of advanced, metastatic melanoma in the USA (October 2015) and in the European Union (December 2015).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
